Microbio Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 11, 2022
Share
Microbio Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 475.26 million compared to TWD 477.09 million a year ago. Revenue was TWD 483.28 million compared to TWD 487.12 million a year ago. Net loss was TWD 560.95 million compared to TWD 813.07 million a year ago. Basic loss per share from continuing operations was TWD 1.0037 compared to TWD 1.4964 a year ago. Diluted loss per share from continuing operations was TWD 1.0037 compared to TWD 1.4964 a year ago.
For the six months, sales was TWD 869.4 million compared to TWD 861.92 million a year ago. Revenue was TWD 885.3 million compared to TWD 879.75 million a year ago. Net income was TWD 246.29 million compared to net loss of TWD 348.73 million a year ago. Basic earnings per share from continuing operations was TWD 0.438 compared to basic loss per share from continuing operations of TWD 0.6478 a year ago. Diluted earnings per share from continuing operations was TWD 0.438 compared to diluted loss per share from continuing operations of TWD 0.6478 a year ago.
Microbio Co., Ltd. is a Taiwan-based company primarily engaged in the research, development, manufacture, distribution and wholesales of healthcare food products and pharmaceuticals. The Company provides fermentation products, including Tien Chun Bao (TCB) oral solutions; herbal products, including LeeHerb series products, as well as organic foods, including vegetables, fruits, nuts, pastry, seasonings, organic meals and others. In addition, it provides new medicines, including anticancer medicines, medicines for hepatitis, allergy, rheumatoid arthritis and others. The Company mainly distributes its products mainly within domestic market.
MICROBIO CO., LTD. 
